Growth Metrics

Protalix BioTherapeutics (PLX) Return on Invested Capital (2023 - 2025)

Historic Return on Invested Capital for Protalix BioTherapeutics (PLX) over the last 3 years, with Q3 2025 value amounting to 0.1%.

  • Protalix BioTherapeutics' Return on Invested Capital rose 3200.0% to 0.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 0.06% for FY2024, which is 2400.0% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Return on Invested Capital of 0.1% as of Q3 2025, which was up 3200.0% from 0.13% recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Return on Invested Capital peaked at 0.13% during Q2 2025, and registered a low of 0.29% during Q2 2024.
  • Its 3-year average for Return on Invested Capital is 0.01%, with a median of 0.08% in 2024.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first tumbled by -400bps in 2024, then surged by 4200bps in 2025.
  • Quarter analysis of 3 years shows Protalix BioTherapeutics' Return on Invested Capital stood at 0.11% in 2023, then crashed by -35bps to 0.07% in 2024, then soared by 43bps to 0.1% in 2025.
  • Its last three reported values are 0.1% in Q3 2025, 0.13% for Q2 2025, and 0.08% during Q1 2025.